invivodata inc. announced the availability of DiaryPRO® Web, its Web-based electronic PRO (ePRO) data collection solution. An extension of invivodata’s handheld ePRO solution (DiaryPRO® 170 Smartphone), DiaryPRO Web provides all of the scientific design and ease-of-use features necessary for capturing valid, reliable patient data in a Web interface. DiaryPRO Web’s patient interface and electronic assessment capabilities, combined with the ability to run on any personal computer with a Web browser, aims to give the power and flexibility to deliver quality data and increased study efficiencies without deploying devices to allpatients.
“DiaryPRO Web shares many of the same design and service elements that have been used in hundreds of DiaryPRO handheld trials to date, including integration with EPX™, our ePRO management system”, said Doug Engfer, President and CEO of invivodata. “We designed DiaryPRO Web primarily to meet the needs of clinical trial sponsors conducting late stage and post-marketing research, where hundreds or thousands of patients are required to collect the safety or efficacy data necessary for post-approval analysis.”
Because the considerations for using a Web-based ePRO solution are different than those using a handheld ePRO solution, invivodata offers scientific and regulatory support to clinical researchers as they make critical decisions about their ePRO modality options.
Including Women of Childbearing Age in Clinical Research
March 26th 2024In recognition of International Women's Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and Marie Teil, Global Head of UCB’s Women of Childbearing Age Program. They speak about the specific challenges women with chronic illnesses face when accessing appropriate treatment and participating in clinical trials, UCB's Women of Childbearing Age Program and it’s most successful strategies, and much more.
FDA Fast Tracks Johnson & Johnson’s Nipocalimab for Fetal Neonatal Alloimmune Thrombocytopenia
March 27th 2024Johnson & Johnson is moving forward with a pair of Phase III trials of nipocalimab to reduce the risk of fetal neonatal alloimmune thrombocytopenia in alloimmunized pregnant patients.
Improving Engagement While Maintaining Data Integrity & Validity
March 19th 2024In recognition of Women's Health Month, we're featuring this recent talk between Associate Editor Miranda Schmalfuhs and uMotif's Chief Product Officer, Julia Lakeland, discuss new technologies improving patient engagement and reducing the emotional and logistical burdens of participation, ethical considerations that should be addressed when implementing those technologies, while ensuring patient privacy, and much more.
The State of the Opioid Epidemic
March 26th 2024In part 1 of this video interview, Greg Sturmer, co-founder and CEO of Elysium Therapeutics discusses the current state of opioid usage including how pain treatment is often mismanaged and how the industry can adopt greater safety standards in developing pain therapies.